Author details

Full Name

Sylvan C Baca

Affiliation

ORCID

Career Start Year

2011

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
38049623	Author Correction: Liquid biopsy epigenomic profiling for cancer subtyping.	Nat Med	2024
36681680	Epigenomic charting and functional annotation of risk loci in renal cell carcinoma.	Nat Commun	2023
36399432	Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes.	Cancer Discov	2023
37857693	Author Correction: A biallelic multiple nucleotide length polymorphism explains functional causality at 5p15.33 prostate cancer risk locus.	Nat Commun	2023
38057321	The PENGUIN approach to reconstruct protein interactions at enhancer-promoter regions and its application to prostate cancer.	Nat Commun	2023
37865722	Liquid biopsy epigenomic profiling for cancer subtyping.	Nat Med	2023
37612286	A biallelic multiple nucleotide length polymorphism explains functional causality at 5p15.33 prostate cancer risk locus.	Nat Commun	2023
37550415	Machine learning for genetics-based classification and treatment response prediction in cancer of unknown primary.	Nat Med	2023
36711812	Utilizing Electronic Health Records (EHR) and Tumor Panel Sequencing to Demystify Prognosis of Cancer of Unknown Primary (CUP) patients.	Res Sq	2023
36546757	Optimized high-throughput screening of non-coding variants identified from genome-wide association studies.	Nucleic Acids Res	2023
34907080	Detecting Neuroendocrine Prostate Cancer Through Tissue-Informed Cell-Free DNA Methylation Analysis.	Clin Cancer Res	2022
35754340	Drug-Induced Epigenomic Plasticity Reprograms Circadian Rhythm Regulation to Drive Prostate Cancer toward Androgen Independence.	Cancer Discov	2022
36071171	Genetic determinants of chromatin reveal prostate cancer risk mediated by context-dependent gene regulation.	Nat Genet	2022
35731919	The Prostate Cancer Androgen Receptor Cistrome in African American Men Associates with Upregulation of Lipid Metabolism and Immune Response.	Cancer Res	2022
35550030	CREB5 reprograms FOXA1 nuclear interactions to promote resistance to androgen receptor-targeting therapies.	Elife	2022
35477723	ASCL1 activates neuronal stem cell-like lineage programming through remodeling of the chromatin landscape in prostate cancer.	Nat Commun	2022
36323882	Integrative molecular analyses define correlates of high B7-H3 expression in metastatic castrate-resistant prostate cancer.	NPJ Precis Oncol	2022
36450752	Extensive androgen receptor enhancer heterogeneity in primary prostate cancers underlies transcriptional diversity and metastatic potential.	Nat Commun	2022
35468964	HOXB13 suppresses de novo lipogenesis through HDAC3-mediated epigenetic reprogramming in prostate cancer.	Nat Genet	2022
34822763	H3K27ac HiChIP in prostate cell lines identifies risk genes for prostate cancer susceptibility.	Am J Hum Genet	2021
33899001	EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer.	Nat Cancer	2021
33785741	Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer.	Nat Commun	2021
33547292	Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma.	Nat Commun	2021
32690948	Prostate cancer reactivates developmental epigenomic programs during metastatic progression.	Nat Genet	2020
31466944	CDK7 Inhibition Suppresses Castration-Resistant Prostate Cancer through MED1 Inactivation.	Cancer Discov	2019
28152275	Qualifiers of atypia in the cytologic diagnosis of thyroid nodules are associated with different Afirma gene expression classifier results and clinical outcomes.	Cancer cytopathology	2017
28464947	Erratum to: Unraveling the clonal hierarchy of somatic genomic aberrations.	Genome Biol	2017
25160065	Unraveling the clonal hierarchy of somatic genomic aberrations.	Genome Biol	2014
25278611	Prostate cancer. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer.	Science	2014
25512523	Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma.	Proc Natl Acad Sci U S A	2014
23622249	Punctuated evolution of prostate cancer genomes.	Cell	2013
23770567	Mutational heterogeneity in cancer and the search for new cancer-associated genes.	Nature	2013
22610119	Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.	Nat Genet	2012
22751462	Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis.	Cancer Res	2012
22649426	The genomic landscape of prostate cancer.	Front Endocrinol (Lausanne)	2012
21978255	Determining membrane capacitance by dynamic control of droplet interface bilayer area.	Langmuir	2011